# A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

> **NCT01982747** · PHASE1 · COMPLETED · sponsor: **Mologen AG** · enrollment: 14 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MGN-Placebo
- **DRUG:** Placebo-MGN

## Key facts

- **NCT ID:** NCT01982747
- **Lead sponsor:** Mologen AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2014-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982747, "A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01982747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*